OBJECTIVE: To investigate the clinic values of combining test of serum matrix metalloproteinase 9 (MMP-9), acetyl heparinase (Hpa) and Cathepsin L (CL) in diagnosis of ovarian cancer. METHODS: Serum levels of MMP-9, Hpa and CL were detected in a total of 418 cases, including 217 cases with ovarian malignant tumor, 100 cases with ovarian benign tumor and 101 healthy controls, by using enzyme-linked immunosorbent assay (ELISA). Their correlation with clinicopathologic feature of ovarian malignant tumor was analyzed and their diagnosis performance was evaluated by receiver operating characteristic (ROC). The combined diagnosis model was established by logistic regression analysis. RESULTS: The serum levels of MMP-9, Hpa and CL were significantly higher in patients with ovarian malignant tumor than in benign tumor and healthy control, the serum levels of CL and Hpa were higher in epithelial cancer than in non-epithelial tumor, and MMP-9, Hpa and CL were elevated in low grade and advanced stage compared to high grade and early stage. The sensitivity for diagnosis of ovarian malignant tumor from high to low was CL, Hpa and MMP-9, and the specificity was MMP-9, CL and Hpa. The united diagnosis model was established and showed the sensitivity and specificity of combined detection were 84.6% and 82.1%, respectively, which were significantly higher than a single tumor marker. CONCLUSION: Serum MMP-9, Hpa and CL were correlated with ovarian malignant tumor and the combined detection of which may be valuable for clinical diagnosis of ovarian malignant tumor.
OBJECTIVE: To investigate the clinic values of combining test of serum matrix metalloproteinase 9 (MMP-9), acetyl heparinase (Hpa) and Cathepsin L (CL) in diagnosis of ovarian cancer. METHODS: Serum levels of MMP-9, Hpa and CL were detected in a total of 418 cases, including 217 cases with ovarian malignant tumor, 100 cases with ovarian benign tumor and 101 healthy controls, by using enzyme-linked immunosorbent assay (ELISA). Their correlation with clinicopathologic feature of ovarian malignant tumor was analyzed and their diagnosis performance was evaluated by receiver operating characteristic (ROC). The combined diagnosis model was established by logistic regression analysis. RESULTS: The serum levels of MMP-9, Hpa and CL were significantly higher in patients with ovarian malignant tumor than in benign tumor and healthy control, the serum levels of CL and Hpa were higher in epithelial cancer than in non-epithelial tumor, and MMP-9, Hpa and CL were elevated in low grade and advanced stage compared to high grade and early stage. The sensitivity for diagnosis of ovarian malignant tumor from high to low was CL, Hpa and MMP-9, and the specificity was MMP-9, CL and Hpa. The united diagnosis model was established and showed the sensitivity and specificity of combined detection were 84.6% and 82.1%, respectively, which were significantly higher than a single tumor marker. CONCLUSION: Serum MMP-9, Hpa and CL were correlated with ovarian malignant tumor and the combined detection of which may be valuable for clinical diagnosis of ovarian malignant tumor.
Entities:
Keywords:
Acetyl heparinase; Cathepsin; Diagnosis; Matrix metalloproteinase 9; Ovarian cancer
Authors: Brian Nolen; Liudmila Velikokhatnaya; Adele Marrangoni; Koen De Geest; Aleksey Lomakin; Robert C Bast; Anna Lokshin Journal: Gynecol Oncol Date: 2010-03-24 Impact factor: 5.482
Authors: Joel Pereira de Moura; Sérgio Mancini Nicolau; João Norberto Stávale; Maria Aparecida da Silva Pinhal; Leandro Luongo de Matos; Edmund Chada Baracat; Geraldo Rodrigues de Lima Journal: Int J Gynecol Cancer Date: 2009-12 Impact factor: 3.437
Authors: L Manenti; P Paganoni; I Floriani; F Landoni; V Torri; A Buda; G Taraboletti; R Labianca; D Belotti; R Giavazzi Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Simon Fredriksson; Joe Horecka; Odd Terje Brustugun; Joerg Schlingemann; Albert C Koong; Rob Tibshirani; Ronald W Davis Journal: Clin Chem Date: 2008-01-02 Impact factor: 8.327
Authors: Paola Matarrese; Barbara Ascione; Laura Ciarlo; Rosa Vona; Carlo Leonetti; Marco Scarsella; Anna M Mileo; Caterina Catricalà; Marco G Paggi; Walter Malorni Journal: Mol Cancer Date: 2010-08-04 Impact factor: 27.401
Authors: Eva Kolwijck; Leon F A G Massuger; Chris M G Thomas; Paul N Span; Marta Krasovec; Janko Kos; Fred C G J Sweep Journal: J Cancer Res Clin Oncol Date: 2009-11-14 Impact factor: 4.553
Authors: Shirley Ralph; Paul E C Brenchley; Angela Summers; Daniela D Rosa; Ric Swindell; Gordon C Jayson Journal: Cancer Sci Date: 2007-04-05 Impact factor: 6.716